Peter Altman - Biocardia CEO
| BCDA Stock | USD 2.46 0.14 6.03% |
CEO
Dr. Peter Altman, Ph.D. is a President, Chief Executive Officer, Principal Executive Officer, Director of the BIOCARDIA, INC.He has served as our President and Chief Executive Officer since 2002, where he has global responsibility for the development, manufacture and marketing of our therapeutic candidates and products. He was founding Chief Executive Officer from 1999 to 2003 and board member of CareDx, a developer of a gene based diagnostics to be used in chronic inflammatory diseases, including cardiac transplantation, coronary artery disease and systemic lupus erythematosus. He was also founding Chief Executive Officer for Lumen Therapeutics from 2004 to 2005, an earlystage pharmaceutical company. He received his Ph.D. in BioengineeringPharmaceutical Chemistry from the University of California, San Francisco and University of California, Berkeley, his Management of Technology certificate from the Walter A. Haas School of Business at the University of California, Berkeley, and both his MS and BS in Mechanical Engineering from the Columbia University School of Engineering and Applied Sciences. Dr. Altman was elected Fellow of the American Heart Association. He has 30 years of experience in life science research and product development, is named inventor in 45 U.S. patents, and has authored 40 scientific publications in cardiology, ophthalmology and spine. since 2016.
| Age | 57 |
| Tenure | 8 years |
| Address | 320 Soquel Way, Sunnyvale, CA, United States, 94085 |
| Phone | 650 226 0120 |
| Web | https://www.biocardia.com |
Latest Insider Transactions
| 2024-12-23 | Acquired 1000 shares @ 2.06 | View | |
| 2024-12-05 | Acquired 250 shares @ 2.22 | View | |
| 2024-11-15 | Acquired 1350 shares @ 1.87 | View | |
| 2024-07-01 | Acquired 300 shares @ 3.05 | View | |
| 2024-06-28 | Acquired 200 shares @ 2.99 | View | |
| 2024-06-21 | Acquired 500 shares @ 3.29 | View | |
| 2024-06-14 | Acquired 500 shares @ 3.52 | View | |
| 2024-06-10 | Acquired 1000 shares @ 3.36 | View | |
| 2024-04-19 | Acquired 183 shares @ 5.55 | View | |
| 2024-03-28 | Acquired 33 shares @ 5.85 | View | |
| 2024-02-13 | Acquired 7207 shares @ 6.9 | View |
Peter Altman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Altman against Biocardia stock is an integral part of due diligence when investing in Biocardia. Peter Altman insider activity provides valuable insight into whether Biocardia is net buyers or sellers over its current business cycle. Note, Biocardia insiders must abide by specific rules, including filing SEC forms every time they buy or sell Biocardia'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Altman few days ago Acquisition by Peter Altman of 1000 shares of Biocardia at 2.06 subject to Rule 16b-3 | ||
Peter Altman over two weeks ago Acquisition by Peter Altman of 41666 shares of Biocardia at 3.0 subject to Rule 16b-3 | ||
Peter Altman over three months ago Acquisition by Peter Altman of 1000 shares of Biocardia at 2.4877 subject to Rule 16b-3 | ||
Peter Altman over three months ago Acquisition by Peter Altman of 3100 shares of Biocardia at 1.87 subject to Rule 16b-3 |
Biocardia Management Efficiency
The company has return on total asset (ROA) of (1.1593) % which means that it has lost $1.1593 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.0362) %, meaning that it created substantial loss on money invested by shareholders. Biocardia's management efficiency ratios could be used to measure how well Biocardia manages its routine affairs as well as how well it operates its assets and liabilities. At present, Biocardia's Return On Capital Employed is projected to increase based on the last few years of reporting. The current year's Return On Equity is expected to grow to 7.58, whereas Return On Tangible Assets are projected to grow to (3.68). At present, Biocardia's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 265.9 K, whereas Total Assets are forecasted to decline to about 2.8 M.Similar Executives
| Found 1 records | CEO Age | ||
| Scott Wolchko | Fate Therapeutics | 54 | |
Management Performance
| Return On Equity | -7.04 | ||||
| Return On Asset | -1.16 |
Biocardia Leadership Team
Elected by the shareholders, the Biocardia's board of directors comprises two types of representatives: Biocardia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biocardia. The board's role is to monitor Biocardia's management team and ensure that shareholders' interests are well served. Biocardia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biocardia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Altman, President CEO, Principal Executive Officer, Director | ||
| Edward Gillis, Senior Devices | ||
| Ian McNiece, Chief Officer | ||
| Sujith Shetty, Chief Regulatory | ||
| Sujith MBBS, Chief Regulatory | ||
| David McClung, Principal Financial and Accounting Officer, Vice President - Finance |
Biocardia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biocardia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.04 | ||||
| Return On Asset | -1.16 | ||||
| Operating Margin | (549.67) % | ||||
| Current Valuation | 6.75 M | ||||
| Shares Outstanding | 4.58 M | ||||
| Shares Owned By Insiders | 14.07 % | ||||
| Shares Owned By Institutions | 2.21 % | ||||
| Number Of Shares Shorted | 83.36 K | ||||
| Price To Earning | (11.00) X | ||||
| Price To Book | 3.86 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Biocardia offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biocardia's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biocardia Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biocardia Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biocardia. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Biocardia Stock refer to our How to Trade Biocardia Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biocardia. If investors know Biocardia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biocardia listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share 0.264 | Quarterly Revenue Growth (0.93) | Return On Assets (1.16) | Return On Equity (7.04) |
The market value of Biocardia is measured differently than its book value, which is the value of Biocardia that is recorded on the company's balance sheet. Investors also form their own opinion of Biocardia's value that differs from its market value or its book value, called intrinsic value, which is Biocardia's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biocardia's market value can be influenced by many factors that don't directly affect Biocardia's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biocardia's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biocardia is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biocardia's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.